Radiation-inducible silencing of uPA and uPAR in vitro and in vivo in meningioma

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 809-816

  Gogineni, Venkateswara Rao ^a   Nalla, Arun Kumar ^a   Gupta, Reshu ^a   Gorantla, Bharathi ^a   Gujrati, Meena ^a   Dinh, Dzung H ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

CArG elements; Meningioma; Radiation inducible promoter; siRNA; uPA; uPAR

Indexed keywords

ACETYLCYSTEINE; HYDROGEN PEROXIDE; MATRIGEL; PLASMID VECTOR; PLASMID VECTOR PCARG; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; MENINGIOMA; MOUSE; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PLASMID; PLASMID PCI NEO; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TANDEM REPEAT; TUMOR CELL LINE; TUMOR VOLUME; UPA GENE; UPAR GENE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OXIDATIVE STRESS; PROMOTER REGIONS, GENETIC; RADIOTHERAPY, ADJUVANT; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77749333027     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000557     Document Type: Article

References (35)

1. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, Park IC, Rhee CH and Hong SI: Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66: 8511-8519, 2006.
2. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M, Mukherjee N, Song Q, Robe P and Chakravarti A: Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 76: 227-237, 2006.
3. Scott SD, Marples B, Hendry JH, Lashford LS, Embleton MJ, Hunter RD, Howell A and Margison GP: A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther 7: 1121-1125, 2000.
4. Worthington J, McCarthy HO, Barrett E, Adams C, Robson T and Hirst DG: Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 6: 673-680, 2004.
5. Marignol L, Coffey M, Hollywood D and Lawler M: Radiation to control transgene expression in tumors. Cancer Biol Ther 6: 1005-1012, 2007.
6. Hallahan DE, Sukhatme VP, Sherman ML, Virudachalam S, Kufe D and Weichselbaum RR: Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci USA 88: 2156-2160, 1991.
7. Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP and Kufe DW: Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res 54: 4266-4269, 1994.
8. Datta R, Rubin E, Sukhatme V, Qureshi S, Hallahan D, Weichselbaum RR and Kufe DW: Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA 89: 10149-10153, 1992.
9. McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG and Robson T: p21(WAF1)-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 14: 246-255, 2007.
10. Boothman DA, Lee IW and Sahijdak WM: Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of X-ray-responsive elements for gene therapy. Radiat Res 138: S68-S71, 1994.
11. Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG and Scott SD: Hypoxia- and radiation-activated Cre/loxP 'molecular switch' vectors for gene therapy of cancer. Gene Ther 13: 206-215, 2006.
12. Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH and Mauceri HJ: Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol 3: 665-671, 2002.
13. Tsurushima H, Yuan X, Dillehay LE and Leong KW: Radiationinducible caspase-8 gene therapy for malignant brain tumors. Int J Radiat Oncol Biol Phys 71: 517-525, 2008.
14. Joki T, Nakamura M and Ohno T: Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum Gene Ther 6: 1507-1513, 1995.
15. Scott SD, Joiner MC and Marples B: Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy. Gene Ther 9: 1396-1402, 2002.
16. Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S and Hirst DG: The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther 15: 495-503, 2008.
17. Gondi CS, Lakka SS, Dinh D, Olivero W, Gujrati M and Rao JS: Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 1: 165-176, 2004.
18. Kargiotis O, Chetty C, Gogineni V, Gondi CS, Pulukuri SM, Kyritsis AP, Gujrati M, Klopfenstein JD, Dinh DH and Rao JS: uPA/uPAR downregulation inhibits radiation-induced migration, invasion and angiogenesis in IOMM-Lee meningioma cells and decreases tumor growth in vivo. Int J Oncol 33: 937-947, 2008.
19. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, Gujrati M and Rao JS: RNA Interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280: 36529-36540, 2005.
20. Duffy MJ, Maguire TM, McDermott EW and O'Higgins N: Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 71: 130-135, 1999.
21. Steiner E, Pollow K, Hasenclever D, Schormann W, Hermes M, Schmidt M, Puhl A, Bruiport M, Bauer A, Petry IB, Koelbl H and Hengstler JG: Role of uorkinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Gynecol Oncol 108: 569-576, 2008.
22. Gondi CS and Rao JS: Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol Biol 487: 267-281, 2009.
23. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
24. Pulukuri SM and Rao JS: Small interfering RNA directed reversal of urokinase plasminogen activator demethylation inhibits prostate tumor growth and metastasis. Cancer Res 67: 6637-6646, 2007.
25. Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC, Gujrati M and Rao JS: Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 22: 5967-5975, 2003.
26. Gogineni VR, Kargiotis O, Klopfenstein JD, Gujrati M, Dinh DH and Rao JS: RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells. Int J Oncol 34: 209-218, 2009.
27. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M and Rao JS: Intraperitoneal injection of an hpRNA-expressing plasmid targeting uPAR and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 13: 4051-4060, 2007.
28. Kunigal S, Lakka SS, Gondi CS, Estes N and Rao JS: RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 121: 2307-2316, 2007.
29. DeTommasi A, Occhiogrosso M, De TC, Cimmino A, Sanguedolce F and Vailati G: Radiation-induced intracranial meningiomas: review of six operated cases. Neurosurg Rev 28: 104-114, 2005.
30. Umansky F, Shoshan Y, Rosenthal G, Fraifeld S and Spektor S: Radiation-induced meningioma. Neurosurg Focus 24: E7, 2008.
31. Sonveaux P, Frerart F, Bouzin C, Brouet A, Dewever J, Jordan BF, Gallez B and Feron O: Irradiation promotes Akt-targeting therapeutic gene delivery to the tumor vasculature. Int J Radiat Oncol Biol Phys 67: 1155-1162, 2007.
32. Marples B, Scott SD, Hendry JH, Embleton MJ, Lashford LS and Margison GP: Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 7: 511-517, 2000.
33. Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R and Kufe DW: Reactive oxygen intermediates target CC(A/T) 6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation. Proc Natl Acad Sci USA 90: 2419-2422, 1993.
34. Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE, Manan A, Hellman S, Posner MC, Kufe DW and Weichselbaum RR: Transcriptional control of viral gene therapy by cisplatin. J Clin Invest 110: 403-410, 2002.
35. Zagurovskaya M, Shareef MM, Das A, Reeves A, Gupta S, Sudol M, Bedford MT, Prichard J, Mohiuddin M and Ahmed MM: EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells. Oncogene 28: 1121-1131, 2009.